Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.59 |
| ▸ | ITK | Q08881 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445893 | 0.97 | LRRK2 (0.58) | LRRK2ITKNPC1MAPTRAB9A | |
| SCHEMBL22445832 | 0.86 | LRRK2 (0.59) | LRRK2ITKNPC1RAB9AJAK2 | |
| SCHEMBL22445881 | 0.83 | LRRK2 (0.58) | LRRK2ITKNPC1RAB9AAURKA | |
| SCHEMBL22445913 | 0.83 | LRRK2 (0.58) | LRRK2ITKNPC1RAB9AJAK2 | |
| SCHEMBL22445924 | 0.82 | LRRK2 (0.59) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL22445863 | 0.81 | LRRK2 (0.58) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL14514347 | 0.79 | ITK (0.67) | LRRK2ITKAURKAJAK2JAK1 | |
| SCHEMBL8252848 | 0.78 | LRRK2 (0.61) | LRRK2ITKNPC1RAB9AAURKA | |
| SCHEMBL8251866 | 0.78 | JAK2 (0.74) | LRRK2ITKNPC1RAB9AAURKA | |
| SCHEMBL5379148 | 0.77 | JAK2 (0.65) | LRRK2ITKAURKAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885ITK 3296/4885NPC1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.